Quince Therapeutics (QNCX) Competitors $1.49 +0.02 (+1.36%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends QNCX vs. ANNX, CRVS, ATAI, CMPS, RZLT, DRUG, AVIR, AQST, OLMA, and NGNEShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Annexon (ANNX), Corvus Pharmaceuticals (CRVS), Atai Life Sciences (ATAI), COMPASS Pathways (CMPS), Rezolute (RZLT), Bright Minds Biosciences (DRUG), Atea Pharmaceuticals (AVIR), Aquestive Therapeutics (AQST), Olema Pharmaceuticals (OLMA), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Annexon Corvus Pharmaceuticals Atai Life Sciences COMPASS Pathways Rezolute Bright Minds Biosciences Atea Pharmaceuticals Aquestive Therapeutics Olema Pharmaceuticals Neurogene Quince Therapeutics (NASDAQ:QNCX) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations. Does the MarketBeat Community favor QNCX or ANNX? Annexon received 48 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 77.46% of users gave Annexon an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes7100.00% Underperform VotesNo VotesAnnexonOutperform Votes5577.46% Underperform Votes1622.54% Does the media refer more to QNCX or ANNX? In the previous week, Annexon had 10 more articles in the media than Quince Therapeutics. MarketBeat recorded 11 mentions for Annexon and 1 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.89 beat Annexon's score of 0.09 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Quince Therapeutics Very Positive Annexon Neutral Do analysts rate QNCX or ANNX? Quince Therapeutics presently has a consensus price target of $9.50, indicating a potential upside of 537.58%. Annexon has a consensus price target of $15.80, indicating a potential upside of 506.53%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Quince Therapeutics is more favorable than Annexon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Annexon 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is QNCX or ANNX more profitable? Annexon's return on equity of -38.99% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% Annexon N/A -38.99%-33.90% Which has higher earnings and valuation, QNCX or ANNX? Annexon is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.24-1.20AnnexonN/AN/A-$134.24M-$1.02-2.55 Do insiders & institutionals believe in QNCX or ANNX? 30.8% of Quince Therapeutics shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by insiders. Comparatively, 12.7% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, QNCX or ANNX? Quince Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. SummaryQuince Therapeutics beats Annexon on 10 of the 16 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.56M$3.15B$5.83B$8.43BDividend YieldN/A1.51%4.89%3.97%P/E Ratio-1.2029.4225.1319.30Price / SalesN/A405.82386.13117.74Price / CashN/A168.6838.0534.62Price / Book0.753.497.374.30Net Income-$31.39M-$71.55M$3.18B$246.62M7 Day Performance12.03%-4.70%-2.86%-3.59%1 Month Performance-10.78%-12.08%-7.46%-7.01%1 Year Performance23.14%-21.15%13.75%5.38% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics2.4417 of 5 stars$1.49+1.4%$9.50+537.6%+25.6%$65.56MN/A-1.2060Positive NewsANNXAnnexon2.0489 of 5 stars$2.39-9.5%$15.80+561.1%-57.9%$254.76MN/A-2.2860Earnings ReportAnalyst ForecastNews CoverageCRVSCorvus Pharmaceuticals2.8495 of 5 stars$3.95-2.2%$12.38+213.3%+85.2%$253.82MN/A-4.2530Positive NewsATAIAtai Life Sciences3.3217 of 5 stars$1.50-12.8%$9.00+500.0%-25.8%$251.70M$331,000.00-1.8580Gap UpCMPSCOMPASS Pathways1.8314 of 5 stars$3.67-6.6%$21.83+494.9%-66.5%$251.11MN/A-1.67120Earnings ReportAnalyst ForecastShort Interest ↑RZLTRezolute2.8856 of 5 stars$4.14-6.5%$24.38+488.8%+109.4%$250.62MN/A-3.3940Positive NewsDRUGBright Minds Biosciences3.4018 of 5 stars$34.92-6.2%$84.33+141.5%+1,784.8%$245.98MN/A-205.40N/ANews CoverageAVIRAtea Pharmaceuticals3.2579 of 5 stars$2.90-4.3%$6.88+137.2%-28.2%$244.94MN/A-1.4070AQSTAquestive Therapeutics1.6171 of 5 stars$2.65-5.4%$11.00+315.1%-34.7%$241.62M$58.90M-5.89160Positive NewsOLMAOlema Pharmaceuticals2.8264 of 5 stars$4.21-3.7%$28.75+582.9%-71.2%$241.23MN/A-1.9270NGNENeurogene2.9563 of 5 stars$16.21-8.4%$60.83+275.3%-57.6%$240.80M$925,000.000.0090Upcoming EarningsShort Interest ↓News CoveragePositive News Related Companies and Tools Related Companies Annexon Alternatives Corvus Pharmaceuticals Alternatives Atai Life Sciences Alternatives COMPASS Pathways Alternatives Rezolute Alternatives Bright Minds Biosciences Alternatives Atea Pharmaceuticals Alternatives Aquestive Therapeutics Alternatives Olema Pharmaceuticals Alternatives Neurogene Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QNCX) was last updated on 3/5/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
